Loading
ASNS (Asparagine synthetase [glutamine-hydrolysing]) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer.
Catalyses the ATP-dependent synthesis of L-asparagine from L-aspartate, using L-glutamine as a source of nitrogen. Can also use ammonia as the nitrogen source in vitro.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming Asparaginase.
In plain words · ASNS (Asparagine synthetase [glutamine-hydrolysing]) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer.
ASNS (Asparagine synthetase [glutamine-hydrolysing]) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer.
Catalyses the ATP-dependent synthesis of L-asparagine from L-aspartate, using L-glutamine as a source of nitrogen. Can also use ammonia as the nitrogen source in vitro.
No product in this corpus aims at ASNS yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the roles drug-target, biomarker; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA ASNS: RNA tissue enhanced (pancreas 114 nTPM); blood lineage group enriched (B-cells 9 nTPM, T-cells 14 nTPM); high antibody staining in 5 normal tissues; highest cancer staining colorectal cancer (3 of 11 high). Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Ovarian cancer); Open Targets associates it with 0 specific cancer types at or above 0.5. (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas ASNS tissue; Open Targets ENSG00000070669 associations
First described 1987. Earliest sequence paper UniProt cites for the protein: Andrulis I.L. et al, Mol. Cell. Biol, 1987, "Isolation of human cDNAs for asparagine synthetase and expression in Jensen rat sarcoma cells". Source.
Sources: HGNC HGNC:753 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P08243 (protein name, function text, keywords and locations (REST API)); CIViC gene ASNS (1 evidence items, 0 assertions, 1 variants; diseases: Ovarian Cancer (GraphQL API, CC0))
Catalyses the ATP-dependent synthesis of L-asparagine from L-aspartate, using L-glutamine as a source of nitrogen. Can also use ammonia as the nitrogen source in vitro. Locus 7q21.3 (HGNC).
RNA: tissue enhanced (pancreas 114 nTPM), detected in all normal tissues. Blood: group enriched (B-cells 9 nTPM, T-cells 14 nTPM).
Medium: Appendix, Caudate, Cerebral cortex, Cervix, Epididymis, Gallbladder, Lymph node, Rectum.
Medium only: breast cancer, carcinoid, cervical cancer, endometrial cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"ASNS" OR ABSTRACT:"ASNS" OR TITLE:"asparagine synthetase glutamine-hydrolyzing" OR ABSTRACT:"asparagine synthetase glutamine-hydrolyzing" OR TITLE:"Asparagine synthetase [glutamine-hydrolyzing]" OR ABSTRACT:"Asparagine synthetase [glutamine-hydrolyzing]") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ASNS, not a curated reading list.